CDK4 and breast cancer: Interestingly, in a syngeneic breast cancer model, CDK4/6 inhibition led to a significant reduction in the frequency and absolute number of tumor-infiltrating CD4+CD25+ Tregs, while other T cell subsets were unaffected (108), suggesting that Tregs are the most susceptible T cell subset to the anti-proliferative effects of CDK4/6i.